KaydedilenlerDerginizi ekleyin

Dergiler / İstanbul Kuzey Klinikleri / 2018 / Cilt: 5 - Sayı: 1

Investigation of Genotoxicity Risk and DNA Repair Capacity in Breast Cancer Patients Using Anastrozole

Fatih AYDOĞAN
Semra ŞARDAŞ
Tuğçe YEŞİL DEVECİOĞLU
Gülden Zehra OMURTAG
Nuran Şenel BEŞE
Sayfa
6–13
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Susceptibility to H2O2 damage was observed to increase with age (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:OBJECTIVE: Breast cancer is the most common cancer in women worldwide and the incidence increases in postmenopausal women.
📊
Temel Bulgular & Veri:Six patients who had taken anastrozole for at least 6 months were retrospectively enrolled, and 12 patients who had not yet received treatment were prospectively enrolled as a control group.
💡
Sonuç & Katkı:Susceptibility to H2O2 damage was observed to increase with age (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

OBJECTIVE: Breast cancer is the most common cancer in women worldwide and the incidence increases in postmenopausal women. Anastrozole is a non-steroidal (type II), third-generation aromatase inhibitor (AI) that is used in the treatment of postmenopausal estrogen-related breast cancer. Several studies have been conducted to assess the efficacy, safety, and superiority of AIs to tamoxifen; however, a literature search did not reveal a study that investigated the genotoxic potential of AIs. The aim of this study was to investigate the possible DNA damage risk profile and individual DNA repair capacity of patients using anastrozole with the modified alkaline comet assay in order to contribute to public health and health economics.METHODS: Women diagnosed with breast cancer after menopause comprised the study group. Six patients who had taken anastrozole for at least 6 months were retrospectively enrolled, and 12 patients who had not yet received treatment were prospectively enrolled as a control group. Peripheral blood lymphocytes were used to measure oxidized DNA damage using formamidopyrimidine DNA-glycosylase (FPG) and endonuclease III (endo III) in a modified comet assay. Individual DNA repair capacity was evaluated with the comet assay after a hydrogen peroxide (H202) challenge to examine the difference in DNA damage susceptibility.RESULTS: Analysis of DNA damage, oxidative base damage, susceptibility to DNA damage, and repair capacity revealed no significant difference between the control group and the patients taking anastrozole (p>0.05). Susceptibility to H2O2 damage was observed to increase with age (p

🔖

Bu Makaleye Atıf Yap

AYDOĞAN, F., ŞARDAŞ, S., DEVECİOĞLU, T. Y., OMURTAG, G. Z., BEŞE, N. Ş. (2022). Investigation of Genotoxicity Risk and DNA Repair Capacity in Breast Cancer Patients Using Anastrozole. İstanbul Kuzey Klinikleri, Cilt: 5 - Sayı: 1, 6–13. https://ajindex.com/articles/551533

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. World Health Organization. International Agency for Research on Cancer 2016. Avaliable at: http://gco.iarc.fr/today/data/pdf/factsheets/cancers/cancer-fact sheets-15.pdf. Accessed Jun 9, 2017.
  2. Bora Başara B, Güler C, Soytutan İ, Aygün A, Özdemir TA, editors. T.C. Sağlık Bakanlığı Sağlık İstatistikleri Yıllığı 2015. Ankara: Türkiye Cumhuriyeti Sağlık Bakanlığı Sağlık Araştırmaları Genel Müdürlüğü, 2016. Available at: http://www.saglikistatistikleri.gov.tr. Accessed Jan 18, 2018. Chang M. Dual roles of estrogen metabolism in mammary carcinogenesis. BMB Rep 2011;44:423–34.
  3. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001;2:133–40. Key TJ. Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids 2011;76:812–5.
  4. Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer Res 2003;5:239–47.
  5. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270–82.
  6. Dinçol D, Özal G. Meme kanserinde endokrin tedavi. In: Aydın S, Akça T, editors. Tüm Yönleriyle Meme Kanseri. Adana: Nobel Kitabevi; 2011 p. 389–95. Berry J. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Clin Ther 2005;27:1671–84.
  7. Hong Y, Yu B, Sherman M, Yuan YC, Zhou D, Chen S. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol Endocrinol 2007;21:401–14.
  8. Macedo LF, Sabnis G, Brodie A. Aromatase inhibitors and breast cancer. Ann N Y Acad Sci 2009;1155:162–73.
  9. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011;103:1299–309.
  10. Dent SF, Gaspo R, Kissner M, Pritchard KI. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat 2011;126:295–310.
  11. Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev 2008;34:157–74.
  12. Files JA, Ko MG, Pruthi S. Managing aromatase inhibitors in breast cancer survivors: not just for oncologists. Mayo Clin Proc 2010;85:560–6. Rugo HS. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase